Form 4: Passage Bio Director Sondhi Dolan Acquires Stock Options
SEC Form 4 Filing
Director Sondhi Dolan acquired stock options in Passage Bio, Inc. on May 21, 2024.
Summary
- On May 21, 2024, director Sondhi Dolan acquired 39,092 stock options in Passage Bio, Inc. at an exercise price of $1.28.
- The options vest on the earlier of the one-year anniversary of the grant date or the date of the issuer's 2025 Annual Meeting, contingent upon continuous service to the issuer.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard transaction. The acquisition of stock options by a director is generally viewed as a positive signal, but it's not a major event.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.
Stakeholder Impact
- The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/21/2024 | Date of transaction: Sondhi Dolan acquired stock options. |
| 05/21/2024 | Grant date of the stock options. |
| 05/21/2034 | Expiration date of the stock options. |
| 2025 Annual Meeting | The stock options vest on the earlier of the one-year anniversary of the grant date or the date of the issuer's 2025 Annual Meeting of its stockholders. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.